Initial Statement of Beneficial Ownership (3)
February 14 2017 - 6:12PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Kutok Jeffery
|
2. Date of Event Requiring Statement (MM/DD/YYYY)
2/10/2017
|
3. Issuer Name
and
Ticker or Trading Symbol
INFINITY PHARMACEUTICALS, INC. [INFI]
|
(Last)
(First)
(Middle)
C/O INFINITY PHARMACEUTICALS, INC., 784 MEMORIAL DRIVE.
|
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director
_____ 10% Owner
___
X
___ Officer (give title below)
_____ Other (specify below)
Chief Scientific Officer /
|
(Street)
CAMBRIDGE, MA 02139
(City)
(State)
(Zip)
|
5. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4)
|
2. Amount of Securities Beneficially Owned
(Instr. 4)
|
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
|
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Common Stock
|
2072.97
|
I
|
By 401(k)
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4)
|
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
|
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
|
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Stock Option (Right to Buy)
|
1/4/2011
(1)
|
1/4/2021
|
Common Stock
|
6583
|
$5.94
|
D
|
|
Stock Option (Right to Buy)
|
1/6/2012
(2)
|
1/6/2022
|
Common Stock
|
9968
|
$7.93
|
D
|
|
Stock Option (Right to Buy)
|
(2)
|
3/2/2022
|
Common Stock
|
4300
|
$8.12
|
D
|
|
Stock Option (Right to Buy)
|
(2)
|
1/4/2023
|
Common Stock
|
10113
|
$36.85
|
D
|
|
Stock Option (Right to Buy)
|
(3)
|
8/6/2023
|
Common Stock
|
18000
|
$22.55
|
D
|
|
Stock Option (Right to Buy)
|
(4)
|
1/10/2024
|
Common Stock
|
15000
|
$12.91
|
D
|
|
Stock Option (Right to Buy)
|
(5)
|
1/14/2025
|
Common Stock
|
31095
|
$15.74
|
D
|
|
Stock Option (Right to Buy)
|
(6)
|
1/6/2026
|
Common Stock
|
32589
|
$6.71
|
D
|
|
Explanation of Responses:
|
(
1)
|
The option vested as to 12/48th of the shares on January 4, 2012 and vested as to 1/48th of the shares at the end of each calendar month thereafter. The option has fully vested.
|
(
2)
|
The option vested in equal monthly installments over four years beginning at the end of the calendar month during which the grant was made. The option has fully vested.
|
(
3)
|
The option vests as to 1/48th of the shares on August 31, 2013 and vests as to 1/48th of the shares at the end of each calendar month thereafter.
|
(
4)
|
The option vests as to 1/48th of the shares on January 31, 2014 and vests as to 1/48th of the shares at the end of each calendar month thereafter.
|
(
5)
|
The option vests as to 1/48th of the shares on January 31, 2015 and vests as to 1/48th of the shares at the end of each calendar month thereafter.
|
(
6)
|
The option vests as to 1/48th of the shares on January 31, 2016 and vests as to 1/48th of the shares at the end of each calendar month thereafter.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Kutok Jeffery
C/O INFINITY PHARMACEUTICALS, INC.
784 MEMORIAL DRIVE.
CAMBRIDGE, MA 02139
|
|
|
Chief Scientific Officer
|
|
Signatures
|
/s/Jeffery Kutok
|
|
2/14/2017
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 5(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Infinity Pharmaceuticals (NASDAQ:INFI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Infinity Pharmaceuticals (NASDAQ:INFI)
Historical Stock Chart
From Sep 2023 to Sep 2024